- Home
- KOS vs INBX Comparison
KOS vs INBX Comparison
Compare KOS & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KOS | INBX |
|---|---|---|
| Founded | 2003 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2011 | 2024 |
Fundamental Metrics
Financial Performance| Metric | KOS | INBX |
|---|---|---|
| Price | $2.76 | $108.37 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 3 |
| Target Price | $1.91 | ★ $150.00 |
| AVG Volume (30 Days) | ★ 10.4M | 326.6K |
| Earning Date | 05-05-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,288,352,000.00 | $1,300,000.00 |
| Revenue This Year | $27.11 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $0.84 | $27.12 |
| 52 Week High | $3.34 | $155.29 |
Technical Indicators
Market Signals| Indicator | KOS | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 49.75 | 49.61 |
| Support Level | $2.66 | $96.60 |
| Resistance Level | $3.09 | $153.14 |
| Average True Range (ATR) | 0.13 | 8.01 |
| MACD | -0.02 | -2.50 |
| Stochastic Oscillator | 26.60 | 38.52 |
Price Performance
Historical ComparisonAbout KOS Kosmos Energy Ltd. (DE)
Kosmos Energy Ltd is a deepwater exploration and production company focused on meeting the world's growing demand for energy. It has diversified oil and gas production from assets offshore Ghana, Equatorial Guinea, Mauritania, Senegal and the Gulf of America. The Company had operations in four geographic reporting segments: Ghana, Equatorial Guinea, Mauritania/Senegal and the Gulf of America. The majority of revenue is derived from the Ghana segment.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.